Pimozide is a serotonin reuptake inhibitor, and combining it with fluoxetine creates an unacceptable risk of serotonin syndrome

Pimozide is a first-generation antipsychotic (diphenylbutylpiperidine) with potent dopamine D2 antagonism. It is not a serotonin reuptake inhibitor. Misidentifying pimozide's drug class leads to an incorrect risk assessment. The actual danger is the CYP2D6-mediated pharmacokinetic interaction causing elevated pimozide levels and QTc prolongation.

Fluoxetine and its active metabolite norfluoxetine are potent CYP2D6 inhibitors; since pimozide is metabolized by CYP2D6 and CYP3A4 through parallel pathways, this combination significantly increases pimozide levels and amplifies its dose-dependent QTc prolongation risk to potentially fatal levels

Pimozide is metabolized by CYP2D6 and CYP3A4 through parallel pathways, with a well-established, dose-dependent risk of QTc prolongation and torsades de pointes through cardiac potassium channel blockade. Fluoxetine's potent inhibition of CYP2D6 would substantially impair pimozide clearance, effectively increasing plasma levels and magnifying the QTc-prolonging effect. (Note: CYP3A4 inhibitors like macrolide antibiotics also increase pimozide levels and QTc risk.) This is a contraindicated combination with a black-box level warning. An alternative antidepressant with minimal CYP2D6 inhibition, such as sertraline or escitalopram, should be selected.

Fluoxetine directly blocks cardiac hERG potassium channels at therapeutic doses, and the additive QTc prolongation from two independent potassium channel blockers makes this combination dangerous

While the ultimate concern is QTc prolongation, the primary mechanism of danger is pharmacokinetic. Fluoxetine inhibits CYP2D6-mediated pimozide metabolism, raising pimozide concentrations. Fluoxetine itself has minimal direct QTc-prolonging effect at standard doses. The danger comes from elevated pimozide levels, not from additive direct channel blockade.

Fluoxetine induces CYP2D6 activity, which accelerates pimozide metabolism and causes subtherapeutic levels with breakthrough tics

Fluoxetine INHIBITS CYP2D6, it does not induce it. The interaction raises pimozide levels, not lowers them. Reversing the direction of this interaction is a critical error. Prescribing the combination under the mistaken belief that it would lower pimozide levels could expose the patient to life-threatening QTc prolongation and cardiac arrhythmia.